This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Public Health  • World Health  • Alert me on articles by topic

Arch Ophthalmol. 2005;123(5):687-688.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New England Journal of Medicine

Mass Treatment With Single-Dose Azithromycin for Trachoma

Anthony W. Solomon, MB, BS, PhD; Martin J. Holland, PhD; Neal D. E. Alexander, PhD; Patrick A. Massae, DCEH; Aura Aguirre, PhD; Angels Natividad-Sancho, MSc; Sandra Molina, MSc; Salesia Safari, MD; John F. Shao, MD, PhD; Paul Courtright, DrPH; Rosanna W. Peeling, PhD; Sheila K. West, PhD; Robin L. Bailey, FRCP, PhD; Allen Foster, FRCS, FRCOphth; David C. W. Mabey, DM, FRCP

Background:  Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model.

Methods:  We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Frequency of Antibiotic Coverage and Elimination of Blinding Trachoma
Sommer
Arch Ophthalmol 2008;126:1000-1001.
FULL TEXT